Search Results

Switching Australian patients with moderate to severe inflammatory bowel disease from originator to biosimilar infliximab: a multicentre, parallel cohort study.

• Authors : Haifer C; St Vincent's Hospital Sydney, Sydney, NSW.; The University of Sydney, Sydney, NSW.

Subjects: Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/Biosimilar Pharmaceuticals/*therapeutic use ; Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*therapeutic use ; Inflammatory Bowel Diseases/Inflammatory Bowel Diseases/Inflammatory Bowel Diseases/*drug therapy

• Source: The Medical journal of Australia [Med J Aust] 2021 Feb; Vol. 214 (3), pp. 128-133. Date of Electronic Publication: 2020 Oct 17.Publisher: Australasian Medical Publishing Co Country of Publication: Australia NLM ID: 0400714 Publication Model:

Record details

Sequential Use of High-Dose Tofacitinib After Infliximab Salvage Therapy in Acute Severe Ulcerative Colitis.

• Authors : Gilmore R; Department of Gastroenterology, Austin Health, Melbourne, Australia.; Hilley P

Subjects: Colitis, Ulcerative/Colitis, Ulcerative/Colitis, Ulcerative/*drug therapy ; Gastrointestinal Agents/Gastrointestinal Agents/Gastrointestinal Agents/*therapeutic use ; Infliximab/Infliximab/Infliximab/*therapeutic use

• Source: Journal of Crohn's & colitis [J Crohns Colitis] 2022 Jan 28; Vol. 16 (1), pp. 166-168.Publisher: Oxford University Press Country of Publication: England NLM ID: 101318676 Publication Model: Print Cited Medium: Internet ISSN:

Record details

Pharmacokinetic Similarity of ABP 710, a Proposed Biosimilar to Infliximab: Results From a Randomized, Single-Blind, Single-Dose, Parallel-Group Study in Healthy Subjects.

• Authors : Chow V; Clinical Pharmacology, Amgen Inc., Thousand Oaks, California, USA.; Oh M

Subjects: Antibodies, Monoclonal/Antibodies, Monoclonal/Antibodies, Monoclonal/*pharmacokinetics ; Antirheumatic Agents/Antirheumatic Agents/Antirheumatic Agents/*pharmacokinetics ; Infliximab/Infliximab/Infliximab/*pharmacokinetics

• Source: Clinical pharmacology in drug development [Clin Pharmacol Drug Dev] 2020 Feb; Vol. 9 (2), pp. 246-255. Date of Electronic Publication: 2019 Oct 19.Publisher: Wiley Country of Publication: United States NLM ID: 101572899 Publication Model: Print-Electronic Cited Medium: Internet ISSN:

Record details

Recent Findings from Austin Health Highlight Research in Inflammatory Bowel Disease (P684 Using a pharmacokinetic simulation model to determine the optimal infliximab intensification strategy to address loss of response in inflammatory bowel ...)

• Source: Immunotherapy Weekly. 2024, pages. 4154

Record details

Outcomes out to 12 months after sequential use of high‐dose tofacitinib following infliximab in acute severe ulcerative colitis.

• Authors : Eqbal, Ali¹ ; Hilley, Patrick¹; Choy, Matthew^1,2

Subjects: *ULCERATIVE colitis; *INFLIXIMAB; *TERTIARY careAUSTRALIA

• Source: Internal Medicine Journal. Aug2023, Vol. 53 Issue 8, p1497-1500. 4p.

Record details

Investigators at Liverpool Hospital Detail Findings in Inflammatory Bowel Disease (Safety, Satisfaction and Cost Savings of Accelerated Infusions of Standard and Intensified-dose Infliximab for Inflammatory Bowel Disease).

• Source: Immunotherapy Weekly. 2023, pages. 2631

Record details

Researcher at Monash University Releases New Study Findings on Inflammatory Bowel Disease (P502 Application of an algorithm-based precision-dosing model to a real-world cohort of patients on infliximab maintenance therapy: implications for drug ...)

• Source: Immunotherapy Weekly. 2023, pages. 5733

Record details

St Vincent's Hospital Researcher Describes Findings in Inflammatory Bowel Disease (P753 Comparing long-term outcomes in inflammatory bowel disease patients between switch and non-switch cohorts: no differences in infliximab persistence or ...)

• Source: Immunotherapy Weekly. 2023, pages. 6556

Record details

Real-world experience with subcutaneous infliximab: broadening treatment strategies for inflammatory bowel disease.

• Authors : Smith, Philip J.; Fumery, Mathurin; Leong, Rupert W.

Subjects: INFLAMMATORY bowel diseases; DRUG monitoring; TUMOR necrosis factorsAUSTRALIA

• Source: Expert Review of Clinical Immunology; 2023, Vol. 19 Issue 9, p1143-1156, 14p

Record details

Studies from University of Sydney Further Understanding of Ulcerative Colitis (P564 vedolizumab versus infliximab and adalimumab in the real-world persistence in Ulcerative Colitis and Crohn's disease - a meta-analysis).

• Source: Immunotherapy Weekly. 2023, pages. 1551

Record details